346
Views
9
CrossRef citations to date
0
Altmetric
Original Research

First-line bevacizumab, cisplatin and vinorelbine plus maintenance bevacizumab in advanced non-squamous non-small cell lung cancer chemo-naïve patients

, MD, , , , , , , & show all
Pages 1389-1396 | Published online: 25 May 2012

Keep up to date with the latest research on this topic with citation updates for this article.

Read on this site (2)

Marta Pérez-De-Lis, Soledad Retamozo, Alejandra Flores-Chávez, Belchin Kostov, Roberto Perez-Alvarez, Pilar Brito-Zerón & Manuel Ramos-Casals. (2017) Autoimmune diseases induced by biological agents. A review of 12,731 cases (BIOGEAS Registry). Expert Opinion on Drug Safety 16:11, pages 1255-1271.
Read now
Simona Malgieri, Salvatore Feliciano, Davide Bosso, Piera Federico, Giovannella Palmieri, Sabino De Placido, Giuseppe Di Lorenzo & Carlo Buonerba. (2012) Non-small cell lung cancer: from targeted therapy to tailored therapy. Expert Opinion on Pharmacotherapy 13:13, pages 1817-1819.
Read now

Articles from other publishers (7)

Jun Wang, Jianpeng Chen, Yan Guo, Baocheng Wang & Huili Chu. (2017) Strategies targeting angiogenesis in advanced non-small cell lung cancer. Oncotarget 8:32, pages 53854-53872.
Crossref
Madhusmita Behera, Rathi N. Pillai, Taofeek K. Owonikoko, Sungjin Kim, Conor Steuer, Zhengjia Chen, Nabil F. Saba, Chandra P. Belani, Fadlo R. Khuri & Suresh S. Ramalingam. (2015) Bevacizumab in Combination with Taxane versus Non-Taxane Containing Regimens for Advanced/Metastatic Nonsquamous Non–Small-Cell Lung Cancer: A Systematic Review. Journal of Thoracic Oncology 10:8, pages 1142-1147.
Crossref
Yuichi Takiguchi, Shunichiro Iwasawa, Koichi Minato, Yosuke Miura, Akihiko Gemma, Rintaro Noro, Kozo Yoshimori, Masato Shingyoji, Mitsunori Hino, Masahiro Ando & Hiroaki Okamoto. (2014) Phase II study of carboplatin, docetaxel and bevacizumab for chemotherapy-naïve patients with advanced non-squamous non-small cell lung cancer. International Journal of Clinical Oncology 20:4, pages 659-667.
Crossref
F. Barlesi, A. Scherpereel, V. Gorbunova, R. Gervais, A. Vikström, C. Chouaid, A. Chella, J.H. Kim, M.J. Ahn, M. Reck, A. Pazzola, H.T. Kim, J.G Aerts, C. Morando, A. Loundou, H.J.M. Groen & A. Rittmeyer. (2014) Maintenance bevacizumab–pemetrexed after first-line cisplatin–pemetrexed–bevacizumab for advanced nonsquamous nonsmall-cell lung cancer: updated survival analysis of the AVAPERL (MO22089) randomized phase III trial. Annals of Oncology 25:5, pages 1044-1052.
Crossref
Esra Ertan, Perihan Göçer, Ali Naycı, Ülkü Çömelekoğlu, Sibel Atış, Rabia Bozdağan Arpacı, Gülden Ersöz, Savaş Körlü & Derya Ümit Talas. (2013) The Effect of Trapidil and Bevacizumab on Tracheal Anastomotic Wound Healing. Current Therapeutic Research 75, pages 5-7.
Crossref
Kyoichi Kaira, Yoshio Tomizawa, Reiko Yoshino, Yosuke Miura, Akihiro Yoshii, Yasuki Iwasaki, Yasuhiko Koga, Akihiro Ono, Takeshi Hisada, Koichi Minato, Koji Sato, Toshifumi Kazama, Shinichi Ishihara, Kenya Kohyama, Naoto Fueki, Ryusei Saito & Noriaki Sunaga. (2013) Phase II study of oral S-1 plus cisplatin with bevacizumab for advanced non-squamous non-small cell lung cancer. Lung Cancer 82:1, pages 103-108.
Crossref
Elizabeth Ann T. Lieser, Gary A. Croghan, Wendy K. Nevala, Michael J. Bradshaw, Svetomir N. Markovic & Aaron S. Mansfield. (2013) Up-regulation of pro-angiogenic factors and establishment of tolerance in malignant pleural effusions. Lung Cancer 82:1, pages 63-68.
Crossref

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.